The market for infectious disease diagnostics is projected to expand from US$ 38,366.38 million in 2022 to US$ 59,954.22 million by 2030, reflecting a compound annual growth rate (CAGR) of 5.7% during the period from 2022 to 2030.
The increasing prevalence of infectious diseases globally, along with the growing use of diagnostics in veterinary medicine, significantly contributes to the expansion of the infectious disease diagnostics market. Nevertheless, challenges such as insufficient reimbursement policies pose obstacles to the growth of this market.
Increasing Incidence of Infectious Diseases Fuels Market Expansion
Infectious diseases can be triggered by various pathogens, including fungi, viruses, parasites, bacteria, and toxins. These diseases have a detrimental impact on public health, leading to increased morbidity, mortality, and economic strain. The rising occurrence of infectious diseases necessitates precise and prompt diagnostic methods, which are essential for effective disease management, treatment, and prevention strategies. Molecular diagnostics, laboratory assays, and point-of-care testing are vital for diagnosing and monitoring a range of infections, including hepatitis C, HIV, tuberculosis, human papillomavirus, and sexually transmitted infections (STIs). The Centers for Disease Control and Prevention (CDC) reports that approximately 10.2 million individuals in African nations seek medical attention for infectious and parasitic diseases annually. An article from the National Library of Medicine (NLM) in 2021 highlighted that infectious diseases remain a significant challenge in many African countries due to a high disease burden and limited healthcare resources. In Nigeria, for instance, over 200 pathogens can cause fever, which is a leading reason for healthcare visits. The World Health Organization (WHO) estimates that around 58 million people globally are affected by chronic hepatitis C, with approximately 1.5 million new cases diagnosed each year. HIV continues to be a critical public health concern worldwide, with The Joint United Nations Programme on HIV/AIDS (UNAIDS) reporting that in 2020, about 37.7 million individuals were living with HIV, including approximately 36 million adults and 1.7 million children aged 0?14 years. Additionally, around 1.5 million new HIV infections were recorded globally in 2020.
According to WHO, tuberculosis (TB) ranks as the 13th leading cause of death worldwide and is the second most lethal infectious disease following COVID-19. In 2020, TB was responsible for 1.5 million deaths, with an estimated 10 million people suffering from the disease globally. Notably, 30 countries with high TB burdens accounted for 86% of new cases, with eight countries?India, China, the Philippines, Indonesia, Nigeria, Pakistan, Bangladesh, and South Africa?comprising two-thirds of the total TB cases. This escalating incidence of infectious diseases underscores the growing demand for diagnostic technologies, including microbial culture, hemagglutination inhibition tests, and enzyme-linked immunosorbent assays (ELISA).
The report categorizes the infectious disease diagnostics market as follows:
The infectious disease diagnostics market is divided by product into kits & reagents, instruments, and software & services. By technology, it is classified into biosensor-based, immunodiagnostics, molecular diagnostics, clinical biology, and others. The immunodiagnostics segment is further divided into enzyme-linked immunosorbent assay, western blotting analysis, and immunofluorescence assay. The molecular diagnostics segment includes polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, next-generation sequencing, DNA microarrays, and others. The market is also segmented by application type into point-of-care testing and laboratory testing, and by testing type into human testing and veterinary testing. The human testing segment is further categorized into HIV, Hepatitis, HAIs, HPV, tuberculosis, influenza, and others. Finally, the market is segmented by end user into diagnostic laboratories, hospitals and clinics, research institutes, homecare settings, and others. Geographically, the market is divided into North America (including the US, Canada, and Mexico), Europe (including the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (including the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (including Brazil, Argentina, and the Rest of South & Central America).
Insights Based on Product
In terms of product segmentation, the infectious disease diagnostics market is categorized into kits & reagents, instruments, and software & services. In 2022, the kits & reagents segment dominated the market share. However, the software & services segment is anticipated to experience the fastest growth rate from 2022 to 2030.
Insights Based on Region
Regionally, the infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the leading region contributing to the global market growth, while Asia Pacific is expected to exhibit the highest CAGR during the forecast period from 2022 to 2030. The growth of the infectious disease diagnostics market in the US is primarily driven by the rising prevalence of infectious diseases, an increasing elderly population, and a growing number of product launches by key industry players. Major companies in the infectious disease diagnostics market include Abbott Laboratories, Bruker Corp, Cardinal Health, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, AccuBioTech Co Ltd, ACON Laboratories, and DiaSorin SpA. These companies are focused on launching new products and expanding geographically to meet the increasing consumer demand and broaden their specialty product portfolios. Their global reach enables them to cater to a vast customer base, thereby facilitating market growth.
Key sources referenced in the preparation of this report on the infectious disease diagnostics market include the World Health Organization (WHO), the US Census Bureau, The Journal for Infectious Diseases, the International Journal of Infectious Diseases, and the CDC, among others.